Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359135 | 0.89 | MAPK1 (0.39) | MAPK1ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL5370647 | 0.85 | ALDH1A1 (0.42) | MAPK1ALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL5370445 | 0.83 | DYRK1A (0.37) | MAPK1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL5362121 | 0.79 | LMNA (0.37) | MAPK1ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL5377787 | 0.77 | POLB (0.45) | ALDH1A1LMNAPOLBTSHRGAA | |
| SCHEMBL5370623 | 0.74 | MAPK1 (0.39) | MAPK1ALDH1A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL5366652 | 0.74 | HPGD (0.38) | ALDH1A1TSHRGAA | |
| SCHEMBL4504044 | 0.71 | ALDH1A1 (0.62) | MAPK1ALDH1A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15426821 | 0.70 | GAA (0.71) | MAPK1ALDH1A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12061812 | 0.70 | GAA (0.66) | MAPK1ALDH1A1CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | MAPK1 1186/4885ALDH1A1 1650/4885CYP2C9 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.